VolitionRx (NYSE:VNRX) Research Coverage Started at StockNews.com

StockNews.com started coverage on shares of VolitionRx (NYSE:VNRX) in a research report sent to investors on Tuesday morning. The brokerage issued a sell rating on the stock.

Separately, Cantor Fitzgerald reaffirmed an overweight rating and issued a $2.50 target price on shares of VolitionRx in a research report on Thursday, May 16th.

VolitionRx Stock Up 3.6 %

Shares of VNRX opened at $0.71 on Tuesday. The company has a market capitalization of $58.45 million, a P/E ratio of -1.53 and a beta of 1.26. The firm has a 50 day moving average of $0.76 and a 200 day moving average of $0.84. VolitionRx has a twelve month low of $0.55 and a twelve month high of $1.79.

VolitionRx (NYSE:VNRX) last announced its quarterly earnings results on Monday, May 13th. The company reported ($0.10) earnings per share for the quarter, beating the consensus estimate of ($0.11) by $0.01. The firm had revenue of $0.17 million for the quarter, compared to the consensus estimate of $0.27 million. On average, sell-side analysts expect that VolitionRx will post -0.34 EPS for the current year.

Institutional Trading of VolitionRx

A hedge fund recently bought a new stake in VolitionRx stock. Silverberg Bernstein Capital Management LLC acquired a new stake in VolitionRx Limited (NYSE:VNRX) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 147,038 shares of the company’s stock, valued at approximately $105,000. Silverberg Bernstein Capital Management LLC owned 0.19% of VolitionRx at the end of the most recent reporting period. 8.09% of the stock is currently owned by institutional investors and hedge funds.

About VolitionRx

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.